Downregulation of glypican-4 facilitates breast cancer progression by inducing cell migration and proliferation

Munir, Javaria; Ngu, Trinh Van; Ayudthaya, Penchatr Diskul Na; Ryu, Seongho

doi:10.1016/j.bbrc.2020.03.064

Cited by 24 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Together with the results from our survival analysis, we can conclude patients of those subtypes have a better prognosis with low levels of GPC4. Due to the partially contradicting results with the study by Munir et al ( 2020 ), we would encourage future research to look at this very relevant topic in more detail and to potentially investigate whether the presence or absence of hormone receptors has further effects on the capability of glypicans to perform their function.…”

Section: Discussionmentioning

confidence: 79%

“…GPC4 is one of the lesser-studied members of the glypican family. A recent study by Munir et al suggested that downregulation of GPC4 could possibly increase cell migration, invasion and proliferative activities in breast cancer (Munir et al 2020 ). Interestingly, the authors showed that knock-down of GPC4 expression in MCF-7 cells using siRNA resulted in more migration activity of the cells.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients

Grillo

Győrffy

Götte

2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Dysregulated expression of proteoglycans influences the outcome and progression of numerous cancers. Several studies have investigated the role of individual glypicans in cancer, however, the impact of the whole glypican family of heparan sulfate proteoglycans on prognosis of a large patient cohort of breast cancer patients has not yet been investigated. In the present study, our aim was to investigate the prognostic power of the glypicans in breast cancer patients. Methods We used a public database including both gene expression data and survival information for 3951 breast cancer patients to determine the prognostic value of glypicans on relapse-free survival using Cox regression analysis. Moreover, we performed quantitative Real-Time PCR to determine glypican gene expression levels in seven representative breast cancer cell lines. Results We found that high GPC3 levels were associated with a better prognosis in overall breast cancer patients. When stratified by hormone receptor status, we found that in worse prognosis subtypes low GPC1 levels correlate with a longer relapse-free survival, and in more favorable subtypes low GPC6 was associated with longer survival. Conclusion Our study concludes that glypicans could act as subtype-specific biomarkers for the prognosis of breast cancer patients and sparks hope for future research on glypicans possibly eventually providing targets for the treatment of the disease.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients

Grillo

Győrffy

Götte

2021

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Knockdown of glypican-4 was found to enhance cell motility, invasion, and growth of breast cancer cells. 25 Another glypican family member, glypican-6, appeared to play a critical role in enhancing invasive migratory potential of breast cancer cells. This was indirectly promoted by stimulation of Wnt5a expression, which in turn led to activation of p38 mitogen-activated protein kinase (MAPK) and Jun N-terminal kinase (JNK).…”

Section: Discussionmentioning

confidence: 99%

Glypican-1 Overexpression in Different Types of Breast Cancers

Alshammari¹,

Al-saraireh²,

Youssef³

et al. 2021

OTT

View full text Add to dashboard Cite

Purpose Treatment of metastatic breast cancer patients is challenging and remains a major underlying cause of female mortality. Understanding molecular alterations in tumor development is critical to identify novel biomarkers and targets for cancer diagnosis and therapy. One of the aberrant cancer expressions gaining recent research interest is glypican-1. Several studies reported strong glypican-1 expression in various types of human cancers. However, none of these investigated glypican-1 expression in a large cohort of breast cancer histopathological subtypes. Patients and Methods Immunohistochemistry was used to assess glypican-1 expression in 220 breast cancer patients and its relation to demographic and clinical features, as well as important prognostic immunohistochemical markers for breast cancer. Results Intense glypican-1 expression was recognized in all breast cancer histopathological subtypes. Normal, healthy breast tissue displayed a heterogeneous low expression (20%). Importantly, a strong differential in glypican-1 expression was determined between normal and malignant breast tissues. Moreover, there was a significantly high rate of glypican-1 expression in advanced grades of breast cancer patients and larger tumor sizes. Unfortunately, the glypican-1 expression demonstrated no obvious relationship with the expression of various biomarkers in breast cancer. Conclusion This study may establish glypican-1 as a promising new therapeutic target for the development of therapy in breast cancer.

show abstract

“…However, a significant reduction of cell surface tethered SDC1 and an increase of shed SDC1 in the ECM has been observed as a function of tumor progression and aggressiveness, suggesting the involvement of post-transcriptional mechanisms in SDC1 expression in this type of tumor. Differential regulation of SDC1 expression as well as of the other SDC isoforms, GPCs, and the other HSPGs has been found in several tumors ( Table 3 ) [ 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 ].…”

Section: Structural Features Biosynthesis and Enzymatic Modificamentioning

confidence: 99%

Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment

Pasquale

Pavone

2020

IJMS

View full text Add to dashboard Cite

In the last few decades, heparan sulfate (HS) proteoglycans (HSPGs) have been an intriguing subject of study for their complex structural characteristics, their finely regulated biosynthetic machinery, and the wide range of functions they perform in living organisms from development to adulthood. From these studies, key roles of HSPGs in tumor initiation and progression have emerged, so that they are currently being explored as potential biomarkers and therapeutic targets for cancers. The multifaceted nature of HSPG structure/activity translates in their capacity to act either as inhibitors or promoters of tumor growth and invasion depending on the tumor type. Deregulation of HSPGs resulting in malignancy may be due to either their abnormal expression levels or changes in their structure and functions as a result of the altered activity of their biosynthetic or remodeling enzymes. Indeed, in the tumor microenvironment, HSPGs undergo structural alterations, through the shedding of proteoglycan ectodomain from the cell surface or the fragmentation and/or desulfation of HS chains, affecting HSPG function with significant impact on the molecular interactions between cancer cells and their microenvironment, and tumor cell behavior. Here, we overview the structural and functional features of HSPGs and their signaling in the tumor environment which contributes to tumorigenesis and cancer progression.

show abstract

Downregulation of glypican-4 facilitates breast cancer progression by inducing cell migration and proliferation

Cited by 24 publications

References 14 publications

Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients

Prognostic impact of the glypican family of heparan sulfate proteoglycans on the survival of breast cancer patients

Glypican-1 Overexpression in Different Types of Breast Cancers

Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment

Contact Info

Product

Resources

About